Literature DB >> 25073536

Colistin nephrotoxicity increases with age.

Ilker Inanc Balkan1, Mustafa Dogan, Bulent Durdu, Ayse Batirel, Ismail N Hakyemez, Birsen Cetin, Oguz Karabay, Ibak Gonen, Ahmet Selim Ozkan, Sami Uzun, Muhammed Emin Demirkol, Sedat Akbas, Asiye Bahar Kacmaz, Sukru Aras, Ali Mert, Fehmi Tabak.   

Abstract

BACKGROUND: Colistin (COL) has become the backbone of the treatment of infections due to extensively drug-resistant (XDR) Gram-negative bacteria. The most common restriction to its use is acute kidney injury (AKI).
METHODS: We conducted a retrospective cohort study to evaluate risk factors for new-onset AKI in patients receiving COL. The cohort consisted of 198 adults admitted to 9 referral hospitals between January 2010 and October 2012 and treated with intravenous COL for ≥ 72 h. Patients with no pre-existing kidney dysfunction were compared in terms of risk factors and outcomes of AKI graded according to the RIFLE criteria. Logistic regression analysis was used to identify associated risk factors.
RESULTS: A total of 198 patients met the inclusion criteria, of whom 167 had no pre-existing kidney dysfunction; the mean patient age was 58.77 (± 18.98) y. Bloodstream infections (34.8%) and ventilator-associated pneumonia (32.3%) were the 2 most common indications for COL use. New-onset AKI developed in 46.1% of the patients, graded as risk (10%), injury (15%), and failure (21%). Patients with high Charlson co-morbidity index (CCI) scores (p = 0.001) and comparatively low initial glomerular filtration rate (GFR) estimations (p < 0.001) were more likely to develop AKI, but older age (p = 0.001; odds ratio 5.199, 95% confidence interval 2.684-10.072) was the major predictor in the multivariate analysis. In-hospital recovery from AKI occurred in 58.1%, within a median of 7 days.
CONCLUSIONS: COL-induced nephrotoxicity occurred significantly more often in patients older than 60 y of age and was related to low initial GFR estimations and high CCI scores, which were basically determined by age.

Entities:  

Keywords:  Colistin; age; nephrotoxicity

Mesh:

Substances:

Year:  2014        PMID: 25073536     DOI: 10.3109/00365548.2014.926021

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  17 in total

1.  Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.

Authors:  Yong Kyun Kim; Jae Ha Lee; Hyun-Kyung Lee; Byung Cheol Chung; Seung Jung Yu; Ho-Young Lee; Jin-Han Park; Sunyoung Kim; Hyeon-Kuk Kim; Sungmin Kiem; Hang-Jea Jang
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 2.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

3.  Good tolerability of high dose colistin-based therapy in patients with haematological malignancies.

Authors:  Sara Grignolo; Paola Tatarelli; Fabio Guolo; Paola Minetto; Giulia Rivoli; Daniela Guardo; Valerio Del Bono; Riccardo Varaldo; Francesca Gualandi; Filippo Ballerini; Annamaria Raiola; Marco Gobbi; Claudio Viscoli; Malgorzata Mikulska
Journal:  Infection       Date:  2017-03-28       Impact factor: 3.553

4.  Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury.

Authors:  Todd A Miano; Ebbing Lautenbach; F Perry Wilson; Wensheng Guo; Yuliya Borovskiy; Sean Hennessy
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 8.237

5.  Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.

Authors:  Moataz M Hassan; Zied Gaifer; Ibrahim S Al-Zakwani
Journal:  Int J Clin Pharm       Date:  2018-03-14

6.  High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.

Authors:  Ali S Omrani; Wafa A Alfahad; Mohamed M Shoukri; Abeer M Baadani; Sultan Aldalbahi; Ali A Almitwazi; Ali M Albarrak
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-01-16       Impact factor: 3.944

7.  Survival or Safety: Balancing act with Colistin.

Authors:  Saiprasad Patil; Kapil Zirpe; Dipnarayan Mukherjee; Anoop Hajare; Krishnaprasad Korukonda; Amit Bhargava
Journal:  J Glob Infect Dis       Date:  2015 Jan-Mar

Review 8.  Colistin for lung infection: an update.

Authors:  Mohan Gurjar
Journal:  J Intensive Care       Date:  2015-01-22

9.  The risk factors of colistin methanesulfonate associated nephrotoxicity.

Authors:  Elif Tükenmez Tigen; E Nursen Koltka; Arzu Dogru; Melek Gura; Haluk Vahabaoglu
Journal:  Indian J Crit Care Med       Date:  2016-06

10.  Clinical and economic outcomes of Acinetobacter vis a vis non-Acinetobacter infections in an Indian teaching hospital.

Authors:  Priyendu Asim; Nagappa Anantha Naik; Varma Muralidhar; K Eshwara Vandana; A Prabhu Varsha
Journal:  Perspect Clin Res       Date:  2016 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.